Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Safety and Efficacy of ENERGI-F703EB Cream in Subjects With Epidermolysis Bullosa

NCT07858422 is registered in ClinicalTrials.gov with Energenesis Biomedical Co., Ltd. as lead sponsor.

NCT NCT07858422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07858422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Safety and Efficacy of ENERGI-F703EB Cream in Subjects With Epidermolysis Bullosa
Lead sponsor
Energenesis Biomedical Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
October 8, 2026
Completion date
June 15, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa, epidermolysis bullosa (eb), epidermolysis bullosa simplex, junctional epidermolysis bullosa